<div id="readability-page-1"><p>DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) is projected to release its  Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $926.3960 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.</p><div><p><span></span><span>Get <strong>DENTSPLY SIRONA</strong> alerts:</span></p></div><h2>DENTSPLY SIRONA Price Performance</h2><ul><li>Dentsply Stock is Repricing Itself </li></ul><p>Shares of XRAY opened at $12.49 on Thursday. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $19.27. The company has a debt-to-equity ratio of 1.36, a current ratio of 1.47 and a quick ratio of 0.99. The stock has a fifty day moving average price of $12.20 and a 200 day moving average price of $12.50. The company has a market cap of $2.49 billion, a P/E ratio of -2.83, a PEG ratio of 0.98 and a beta of 1.01. </p><h2>DENTSPLY SIRONA Announces Dividend</h2><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were issued a $0.16 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 annualized dividend and a yield of 5.1%. DENTSPLY SIRONA's dividend payout ratio  is presently -14.48%. </p><h2>Insiders Place Their Bets</h2><p>In related news, Director Gregory T. Lucier sold 82,200 shares of the company's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own  0.50% of the company's stock. </p><h2>Hedge Funds Weigh In On DENTSPLY SIRONA</h2><p>A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC boosted its holdings in shares of  DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the period.  Armistice Capital LLC lifted its position in  DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier's stock worth $72,790,000 after buying an additional 5,234,587 shares in the last quarter.  Jacobs Levy Equity Management Inc. lifted its position in  DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier's stock worth $58,480,000 after buying an additional 4,003,606 shares in the last quarter.  Goldman Sachs Group Inc. boosted its stake in shares of  DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after buying an additional 2,172,343 shares during the period.  Finally, Marshall Wace LLP grew its holdings in shares of  DENTSPLY SIRONA by 1,032.5% during the 4th quarter. Marshall Wace LLP now owns 2,236,786 shares of the medical instruments supplier's stock valued at $25,566,000 after acquiring an additional 2,039,280 shares in the last quarter. Institutional investors and hedge funds own  95.70% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several research firms have commented on XRAY. UBS Group lowered their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, February 3rd. Stifel Nicolaus  set a $13.00 price objective on shares of DENTSPLY SIRONA in a research note on Thursday, November 6th. JPMorgan Chase &amp; Co. cut their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a &#34;neutral&#34; rating for the company in a research report on Friday, November 7th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Finally, Zacks Research lowered DENTSPLY SIRONA from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Monday, November 10th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, DENTSPLY SIRONA presently has an average rating of &#34;Reduce&#34; and a consensus target price of $14.25.</p><p><b>Read Our Latest Research Report on XRAY</b></p><h2>About DENTSPLY SIRONA</h2> (Get Free Report)<p>Dentsply Sirona Inc <span>NASDAQ: XRAY<span></span></span> is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.  </p><p>The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.</p><h2>See Also</h2><ul><li>Five stocks we like better than DENTSPLY SIRONA</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WFJBWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WFJBWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in DENTSPLY SIRONA Right Now?</h2><p>Before you consider DENTSPLY SIRONA, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.</p><p>While DENTSPLY SIRONA currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

XRAY

<p>DENTSPLY SIRONA (NASDAQ:XRAY) is set to release its Q4 2025 earnings on February 26, with analysts expecting earnings of $0.28 per share and revenue of $926.4 million. The company has a market cap of $2.49 billion and a P/E ratio of -2.83. Recently, it announced a quarterly dividend of $0.16. Institutional investors hold 95.70% of the stock, and analysts have mixed ratings, with an average target price of $14.25. The stock opened at $12.49, with a 12-month range of $9.85 to $19.27.</p>

DENTSPLY SIRONA (XRAY) to Release Quarterly Earnings on Thursday